Literature DB >> 21209627

APOBEC3-mediated hypermutation of retroviral vectors produced from some retrovirus packaging cell lines.

A D Miller1, M J Metzger.   

Abstract

APOBEC3 proteins are packaged into retrovirus virions and can hypermutate retroviruses during reverse transcription. We found that HT-1080 human fibrosarcoma cells hypermutate retroviruses, and that the HT-1080 cell-derived FLYA13 retrovirus packaging cells also hypermutate a retrovirus vector produced using these cells. We found no hypermutation of the same vector produced by the mouse cell-derived packaging line PT67 or by human 293 cells transfected with the vector and retrovirus packaging plasmids. We expect that avoidance of vector hypermutation will be particularly important for vectors used in gene therapy, wherein mutant proteins might stimulate deleterious immune responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21209627      PMCID: PMC3085560          DOI: 10.1038/gt.2010.177

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  19 in total

1.  Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.

Authors:  M Pizzato; O W Merten; E D Blair; Y Takeuchi
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

2.  Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells.

Authors:  Gerry Shaw; Silas Morse; Miguel Ararat; Frank L Graham
Journal:  FASEB J       Date:  2002-04-10       Impact factor: 5.191

3.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

4.  Acutely transforming retrovirus expressing Nras generated from HT-1080 fibrosarcoma cells infected with the human retrovirus XMRV.

Authors:  Michael J Metzger; A Dusty Miller
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

5.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

6.  Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells.

Authors:  Emily C Knouf; Michael J Metzger; Patrick S Mitchell; Jason D Arroyo; John R Chevillet; Muneesh Tewari; A Dusty Miller
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

7.  Species-specific restriction of apobec3-mediated hypermutation.

Authors:  Edward P Browne; Dan R Littman
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

8.  Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses.

Authors:  Samuel J Rulli; Jane Mirro; Shawn A Hill; Patricia Lloyd; Robert J Gorelick; John M Coffin; David Derse; Alan Rein
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

9.  Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.

Authors:  Fransje A Koning; Edmund N C Newman; Eun-Young Kim; Kevin J Kunstman; Steven M Wolinsky; Michael H Malim
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene.

Authors:  Audrey Low; Chioma M Okeoma; Nika Lovsin; Marcelo de las Heras; Thomas H Taylor; B Matija Peterlin; Susan R Ross; Hung Fan
Journal:  Virology       Date:  2009-01-15       Impact factor: 3.616

View more
  1 in total

1.  Construction of stable packaging cell lines for clinical lentiviral vector production.

Authors:  Khaled S Sanber; Sean B Knight; Sam L Stephen; Ranbir Bailey; David Escors; Jeremy Minshull; Giorgia Santilli; Adrian J Thrasher; Mary K Collins; Yasuhiro Takeuchi
Journal:  Sci Rep       Date:  2015-03-12       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.